Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio, Inc. (formerly Nasdaq: KRON) has generated a stream of news centered on its work as a biopharmaceutical and clinical-stage company focused on small molecule therapeutics that address deregulated transcription in cancer and autoimmune diseases. Company announcements describe how its proprietary discovery engine decodes transcription factor regulatory networks to identify druggable cofactors and support oncology and autoimmune programs.
News coverage for KRON has included scientific and pipeline updates, such as preclinical data from p300 lysine acetyltransferase (KAT) inhibitor programs in multiple myeloma, HPV-driven tumors, and autoimmune indications. Releases have detailed how p300 KAT inhibition can modulate pro-inflammatory signaling pathways, influence viral oncogene expression in HPV-driven tumor models, and support candidate selection for conditions such as Sjögren’s disease.
Corporate and strategic developments have also been prominent in Kronos Bio’s news flow. The company has reported decisions to discontinue development of a CDK9 inhibitor in a specific ovarian cancer setting, implement cost reduction strategies and workforce reductions, and evaluate strategic alternatives that could include acquisitions, mergers, or asset sales. These updates provide context on how Kronos Bio has managed its pipeline and resources.
A key news theme for KRON is the company’s acquisition by Concentra Biosciences, LLC. In May 2025, Kronos Bio announced a definitive merger agreement under which a Concentra subsidiary would launch a tender offer for all outstanding shares of Kronos Bio common stock for a cash payment per share plus a non-tradeable contingent value right tied to potential proceeds from specified product candidates and cost savings. A subsequent Form 8-K filed on June 20, 2025, reports that the tender offer was completed and the merger closed, with Kronos Bio becoming a wholly owned subsidiary of Concentra and its shares delisted from Nasdaq.
Investors, researchers, and observers reviewing KRON-related news can use this history to understand Kronos Bio’s scientific focus on deregulated transcription, the evolution of its pipeline, and the sequence of strategic decisions that culminated in its acquisition and delisting. This news archive offers a detailed record of how the company communicated scientific findings, financial results, restructuring measures, and corporate transactions over time.
Kronos Bio, Inc. (Nasdaq: KRON) announced it will present preclinical data on its oral CDK9 inhibitor, KB-0742, at the AACR-NCI-EORTC Virtual International Conference from Oct. 7-10, 2021. This data builds on previous findings and aims to treat MYC-amplified solid tumors. The company anticipates sharing preliminary clinical results from an ongoing Phase 1/2 study in Q4 2021. With CDK9 targeting critical cancer pathways, the upcoming presentation may influence investor sentiment regarding the drug's potential in oncology.
Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Marni Kottle as the senior vice president of Corporate Communications and Investor Relations. With over 20 years of experience, Kottle previously served as vice president of Corporate Communications at Gilead Sciences. Her expertise will enhance Kronos Bio's communications strategy during a critical growth phase. The company focuses on developing therapies for cancer, including its lead investigational drug, entospletinib, for treating NPM1-mutated acute myeloid leukemia.
Kronos Bio, Inc. (Nasdaq: KRON) announced participation in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7 a.m. ET. The event will be webcast live and archived on the company's website for one month. Kronos Bio specializes in therapies aimed at cancer treatment, particularly through their investigational therapies like entospletinib for NPM1-mutated acute myeloid leukemia and KB-0742 for MYC-amplified solid tumors.
Kronos Bio, Inc. announced FDA clearance for its Investigational New Drug application for lanraplenib (LANRA) targeting acute myeloid leukemia (AML). The firm is set to launch a Phase 1/2 clinical trial in Q4 2021 and plans to initiate a Phase 3 trial for entospletinib (ENTO) in newly diagnosed NPM1-mutated AML patients. Financially, as of June 30, 2021, Kronos holds $419.3 million in cash, with a net loss of $29.1 million for Q2 2021. The company showcased its SYK inhibitor portfolio and plans to report key trial data in the coming months.
Kronos Bio has received FDA clearance for its IND application for lanraplenib (LANRA) to treat relapsed or refractory FLT3-mutated acute myeloid leukemia (AML). The first Phase 1/2 trial is set to begin in Q4 2021, with initial safety and efficacy data expected in late 2022. LANRA is positioned as a next-generation SYK inhibitor, with potential advantages in dosing compared to entospletinib (ENTO). The development strategy aims to leverage synergistic effects between LANRA and standard treatments to target genetic mutations in AML patients.
Kronos Bio, Inc. (Nasdaq: KRON) announced participation in two upcoming investor conferences. The management team will engage in fireside chats at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 a.m. ET, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 11:20 a.m. ET. These discussions will be webcast live on the company's website, with replays available for one month after each event. Kronos Bio focuses on developing cancer therapies, including SYK inhibitors and CDK9 inhibitors, to target specific mutations in cancer.
Kronos Bio (KRON) has revealed its development strategy for the SYK inhibitor portfolio, particularly lanraplenib (LANRA) and entospletinib (ENTO), targeting acute myeloid leukemia (AML). The company plans to begin two Phase 1/2 trials for LANRA and a Phase 3 trial for ENTO aimed at patients with NPM1 mutations. Furthermore, initial data from KB-0742, a CDK9 inhibitor for MYC-dependent solid tumors, is expected by Q4 2021. These advancements aim to address the needs of AML patients with specific genetic mutations that account for over two-thirds of cases.
Kronos Bio, Inc. (Nasdaq: KRON) reported significant developments during its recent quarterly update. As of March 31, 2021, the company had $440.6 million in cash and equivalents. Highlights include preclinical data for KB-0742 presented at AACR, indicating sustained tumor growth inhibition in multiple cancers. The FDA approved a positive End-of-Phase 2 meeting for SYK inhibitor entospletinib, paving the way for a Phase 3 trial in AML. R&D expenses were $17.6 million, while the net loss stood at $26.1 million or $0.48 per share.
Kronos Bio, Inc. (Nasdaq: KRON) will participate in a fireside chat at the Bank of America Securities 2021 Health Care Conference on May 13, 2021, at 1:15 p.m. ET. The event will be available via live webcast on the company's website, with a replay archived for one month. Kronos Bio focuses on developing therapies for cancer, with lead investigational therapy entospletinib aimed at treating NPM1-mutated acute myeloid leukemia (AML) and another candidate, KB-0742, targeting MYC-amplified solid tumors.
Kronos Bio, Inc. (Nasdaq: KRON) presented preclinical data at the AACR Annual Meeting 2021 for KB-0742, an innovative CDK9 inhibitor targeting MYC-amplified tumors. The findings indicated sustained tumor growth inhibition via intermittent dosing, with MYC genomic amplification identified as a key sensitivity factor. Initial clinical trial data for KB-0742 is expected in Q4 2021, with hopes to confirm these promising preclinical results translating to effective treatments in patients.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
